GILD vs GSK

Gilead Sciences and GSK plc, both Healthcare

Gilead Sciences is the larger company at $154B against $102B. Over the past year GSK returned +42% against +38% for GILD.

Gilead Sciences and GSK plccompared on valuation, return and Ryufin’s Smart Score
FigureGILDGSK
Last close$148$51.44
Market cap$154B$102B
Dividend yield2.1%n/a
1-year return+38%+42%
5-year return+160%+57%
Ryufin Smart Scoresector-relative, 1–109/109/10

Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.

Gilead Sciences

Revenue of $7.8B in Q2 2026, net income null. Its largest reported line is HIV Product Sales, 55% of the disclosed total.

GILD overviewrevenue and segmentsvaluation

GSK plc

GSK overviewrevenue and segmentsvaluation

Open these two in the interactive comparison to add more names, change the period or read the correlation.